Evidence map›Paper›PMID 41656989›Full record

ArticleActa biochimica et biophysica Sinica2026

Fibroblast growth factor 13 deficiency attenuates doxorubicin-induced cardiotoxicity by regulating Parkin-mediated myocardial injury.

Jiabing Han, Xuyan Li, Yiming Dong, Yidan Wang, Simeng Lv, Yiyi Zhang, Ran Zhao, Yingke Yan, Yanxue Han, Yu Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiabing HanThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Xuyan LiThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Yiming DongThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Yidan WangThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Simeng LvThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Yiyi ZhangThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Ran ZhaoThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Yingke YanThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Yanxue HanThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Yu WangCollege of Basic Medical Science, Hebei University, Baoding 071000, China.
Jing YangZhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou 310000, China.
Cong WangThe Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China.
Chuan WangCentral Laboratory, Affiliated Hospital of Hebei University, Clinical Medical College, Hebei University, Baoding 071000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical use of doxorubicin (DOX) as a chemotherapeutic agent is limited by its cardiotoxic effects. Fibroblast growth factor (FGF) isoform 13, a distinct type of FGF, has been increasingly recognized as an important regulator of cardiovascular disease. However, its role in doxorubicin-induced cardiotoxicity remains unknown. Therefore, the objective of this study is to investigate the role and mechanism of FGF13 in doxorubicin-induced cardiac injury. C57BL/6 mice are used to establish Dox-induced cardiotoxicity models. The results reveal that mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening are decreased in the DOX group. In contrast,

Indexed as

CardiotoxicityDoxorubicinFibroblast Growth FactorsUbiquitin-Protein LigasesAnimalsApoptosisMaleMiceMice, Inbred C57BLMice, KnockoutMyocytes, CardiacDoxorubicinfibroblast growth factor 13Fibroblast Growth Factorsparkin proteinUbiquitin-Protein LigasesapoptosiscardiotoxicityKeywords: FGF13myocardial injuryParkin

Identifiers

PMID41656989
PMCPMC13449084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.